PHLI -- Reports Year End Results
MATAWAN, N.J.--(BUSINESS WIRE)--
PacificHealth Laboratories, Inc. (OTCBB: PHLI), an innovative nutrition technology company, announced revenues of $6,209,846 for the year ended December 31, 2006 versus revenues of $5,444,558 for the same period in 2005. The Company reported net income applicable to common stockholders of $2,258,577, or $0.17 per share fully diluted, for the year ended December 31, 2006 compared to a net loss applicable to common stockholders of ($652,410), or ($0.06) per share, for the year ended December 31, 2005. Net income for the year ended December 31, 2006 included approximately $2,622,000 from a gain on the sale of patents and technology, net of tax effects, to Mott's LLP, a division of Cadbury Schweppes Americas Beverages ("CSAB").
Dr. Robert Portman, President and CEO of PacificHealth said, "2006 was a pivotal year for PacificHealth Labs. We completed an important licensing agreement with CSAB that has greatly improved our long-term prospects. Among the positive outcomes of the transaction was the receipt of an initial fee of $4 million that has been used to eliminate our long-term debt and strengthen our balance sheet. The agreement also provides PHLI with an exclusive, royalty-free license to continue to manufacture and market the powder and gel forms of ACCELERADE(R) and ENDUROX(R) R4(R). The CSAB agreement has enabled us to drastically reduce our marketing and advertising budget and increase funding for the development of new sports performance and weight loss products."
Dr. Portman continued, "During the past year we saw publication of important new studies confirming the superiority of ACCELERADE over conventional sports drinks. Investigators from James Madison and St. Cloud Universities presented the results of studies showing that the patented 4:1 carbohydrate protein formula found in ACCELERADE improves exercise performance, rehydration and muscle recovery. We are confident that the growing body of scientific work supporting the benefits of our products coupled with the launch of ACCELERADE RTD by CSAB will lead to increased sales opportunities both in the U.S. and internationally."
For the three-month period ended December 31, 2006, revenues were $1,113,114 compared to revenues of $735,071 for the same period in 2005. The Company recorded a loss before income taxes of ($383,301) for the three months ended December 31, 2006 compared to a loss before income taxes of ($855,946) for the same period in 2005. The Company recorded a net loss applicable to common stockholders of ($383,301), or ($0.03) per share, for the three months ended December 31, 2006 compared to a net income applicable to common stockholders of $644,578, or $0.06 per share, for the same period in 2005. For the three months and for the year ended December 31, 2005, the Company recorded a net tax benefit of $1,278,000 due to the Company's asset sale to CSAB that closed on February 22, 2006.
Dr. Portman concluded, "We are extremely positive about our prospects for the current year. CSAB is weeks away from its national multi-channel launch of ACCELERADE RTD in the United States. Finally, we recently launched SATIATRIM(R), our ready-to-drink weight loss product via www.satiatrim.com. SATIATRIM represents an exciting new class of diet products that reduces appetite by stimulating the body's natural appetite control mechanisms. SATIATRIM, by eliminating hunger and food cravings, can help individuals stay on their diet until they achieve their target weight. Most importantly, SATIATRIM can make any type of diet more effective."
About PacificHealth Laboratories, Inc.:
PacificHealth Laboratories, Inc. (PHLI.OB), a leading nutrition technology company, has been a pioneer in discovering, developing and commercializing patented, protein-based nutritional products that stimulate specific peptides involved in appetite regulation and that activate biochemical pathways involved in muscle performance and growth. PHLI's principle areas of focus include weight loss, management of Type 2 diabetes and sports performance. To learn more, visit www.pacifichealthlabs.com.
This news release and oral statements made from time to time by Company representatives concerning the same subject matter may contain so-called "forward-looking statements". These statements can be identified by introductory words such as "expects", "plans", "will", "estimates", "forecasts", "projects" or words of similar meaning and by the fact they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing new products and their potential. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known, such general economic conditions, consumer product acceptance and competitive products, and others of which are not. No forward-looking statements are a guarantee of future results or events, and one should avoid placing undue reliance on such statements.
PACIFICHEALTH LABORATORIES, INC.
BALANCE SHEETS
ASSETS
December 31, December 31,
2006 2005
------------ ------------
Current assets:
Cash and cash equivalents $2,564,038 $138,487
Accounts receivable, net 502,234 187,835
Inventories 1,913,275 1,309,779
Prepaid expenses 144,059 119,002
Deferred tax asset - 1,278,000
------------ ------------
Total current assets 5,123,606 3,033,103
Property and equipment, net 74,163 65,357
Deposits 10,895 20,393
------------ ------------
Total assets $5,208,664 $3,118,853
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Notes payable $44,327 $129,944
Accounts payable and accrued expenses 960,757 1,546,958
Deferred revenue 244,197 369,068
------------ ------------
Total current liabilities 1,249,281 2,045,970
------------ ------------
Longterm liabilities:
Convertible notes payable - 500,000
------------ ------------
Stockholders' (deficit) equity:
Preferred stock:
Series A, convertible, no par value;
90,909 shares authorized, ------ issued
and outstanding at December 31, 2006;
90,909 issued and outstanding at
December 31, 2005 - 966,387
Common stock, $.0025 par value;
authorized 50,000,000 shares; issued and
outstanding: 12,776,690 shares at
December 31, 2006 and 10,267,045 shares
at December 31, 2005 31,942 25,667
Additional paid-in capital 17,867,945 15,790,335
Accumulated deficit (13,940,504) (16,209,506)
------------ ------------
3,959,383 572,883
------------ ------------
Total liabilities and stockholders'
equity $5,208,664 $3,118,853
============ ============
PACIFICHEALTH LABORATORIES, INC.
STATEMENTS OF OPERATIONS
FOR THE THREE- AND TWELVE- MONTHS ENDED DECEMBER 31, 2006 AND 2005
(UNAUDITED)
Three Months Twelve Months
Ended December 31, Ended December 31,
----------------------- -----------------------
2006 2005 2006 2005
----------- ----------- ----------- -----------
Revenues:
Net product sales $1,113,114 $735,071 $6,209,846 $5,444,558
Cost of goods sold:
Product sales 785,131 659,416 3,472,955 3,409,664
Write-down of
obsolete inventory - 93,255 - 93,255
----------- ----------- ----------- -----------
Total cost of goods
sold 785,131 752,671 3,472,955 3,502,919
----------- ----------- ----------- -----------
Gross profit 327,983 (17,600) 2,736,891 1,941,639
----------- ----------- ----------- -----------
Selling, general and
administrative
expenses 681,123 763,911 2,917,450 3,721,567
Research and
development expense 54,620 33,087 196,020 195,242
Depreciation expense 7,624 16,214 50,905 64,638
----------- ----------- ----------- -----------
743,367 813,212 3,164,375 3,981,447
----------- ----------- ----------- -----------
Loss before other
income (expense) and
income taxes (415,384) (830,812) (427,484) (2,039,808)
----------- ----------- ----------- -----------
Other income
(expense):
Gain on sale of
patents/technology,
net of expenses of
$90,795 - - 3,909,205 -
Interest income 32,448 281 96,697 4,456
Interest expense (365) (25,415) (31,416) (102,134)
----------- ----------- ----------- -----------
32,083 (25,134) 3,974,486 (97,678)
----------- ----------- ----------- -----------
(Loss) income before
income taxes (383,301) (855,946) 3,547,002 (2,137,486)
(Benefit) provision
for income taxes - (1,505,525) 1,278,000 (1,503,410)
----------- ----------- ----------- -----------
Net (loss) income (383,301) 649,579 2,269,002 (634,076)
Less preferred
dividends - (5,001) (10,425) (18,334)
----------- ----------- ----------- -----------
Net (loss) income
applicable to common
stockholders $(383,301) $644,578 $2,258,577 $(652,410)
=========== =========== =========== ===========
Net (loss) income per
common share - Basic $(0.03) $0.06 $0.19 $(0.06)
=========== =========== =========== ===========
Net (loss) income per
common share -
Diluted $(0.03) $0.06 $0.17 $(0.06)
=========== =========== =========== ===========
Weighted average
shares outstanding -
Basic 12,757,124 10,257,262 11,906,777 10,242,141
=========== =========== =========== ===========
Weighted average
shares outstanding -
Diluted 12,757,124 10,257,262 13,397,154 10,242,141
=========== =========== =========== ===========
Source: PacificHealth Laboratories, Inc.
